About the Book
This handbook is a reference source for identifying, characterizing, instructing on use, and describing outcomes of neurotoxin treatments – to understand mechanisms associated with toxin use; to project outcomes of neurotoxin treatments; to gauge neurotoxins as predictors of events leading to neurodegenerative disorders and as aids to rational use of neurotoxins to model disease entities. Neuroprotection is approached in different manners including those 1) afforded by therapeutic agents – clinical and preclinical; or 2) by non-drug means, such as exercise. The amorphous term ‘neurotoxin’ is discussed in terms of the possible eventuality of a neuroprotectant producing an outcome of excess neuronal survival and a behavioral spectrum that might produce a dysfunction – akin to a neurotoxin’s effect. This new edition significantly expands on the information provided in the first edition, providing the latest research in neurotoxicity and highlighting the relationship between specificneurotoxins and the neurodegenerative disorders they can cause. It also includes new sections on the neurotoxicity of heavy metals, fungi, and snake venom. The Handbook of Neurotoxicity is thus an instructive and valuable guide towards understanding the role of neurotoxins/neurotoxicity in the expansive field of Neuroscience, and is an indispensable tool for laboratory investigators, neuroscientists, and clinical researchers.
Table of Contents:
Cell Death Processes: Neurons and Glia.- Neuronal Necrosis.- Neuronal Apoptosis.- Autophagy Pathways.- Necrostatin Neuroprotection.- Neuronal Necroptosis, Relation to Neurological Disorders.- Multiple Cell Death Processes in Neurological Disorders.- Micorglia: Neuroprotective and Neurodestructive Propertie.s, - Selective Neurotoxins.- Survey of Selective Neurotoxinx .- RCSN Cell System for Identifying Dopaminergic Neurotoxicity.- Neurotoxicity: A complex multistage process.- Dopaminergic and Noradrenergic Neurotoxins.- Dopamine and L-dopa as Selective Endogenous Neurotoxins., Dopamine D2 Receptor Supersensitivity as a non-Degenerative Neurotoxin.- Trace Amine-Associated Receptor 1 (TAAR1) and Doapmine Receptor Sensitivity.- Dopamine Receptor Supersensitivity to Model Schizophrenia.- Pathophysiology of Obsessive-Compulsive Disorder: Insights from Normal Function and Neurotoxic Effects of Drugs, Infection, and Brain Injury.- Dopamine D3 receptors and schizophrenia / drug addiction.- Tardive Dyskinesia: Outcome of Antipsychotic Treatment and Brain Damage?.- 6-Hydroxydopamine Neurotoxicity in Adult Animal.- 6-Hydroxydopamine Neurotoxicity in Perinatal Animals.- 6-Hydroxydopa in Perinatal and Adult Animals.- MPTP Neurotoxicity Mechanisms.- Dopaminergic and Noradrenergic Neurotoxins and Neurodegenerative Disorders.- anti-NGF.- Advances in Stem Cell Research for Parkinson's Disease.- Autophagy Pathways and Parkinson's Disease.- Regulation of DA Homeostasis and Role of VMAT2 in Parkinson's Disease.- Alpha-Synuclein in Parkinson's Disease.- Dopaminergic Neurons in Parkinson's Disease.- Dopamine Oxidation and Parkinson's Disease.- Neuromelanin and Parkinson's Disease., -Iron-Induced Dopaminergic Cell Death in vivo as a Model of Parkinson's Disease.- Iron Neurotoxicity in Parkinson's Disease.- 6-Hydroxydopamine as Preclinical Model of Parkinson's Disease. - MPTP modeling of Parkinson's Disease.- MPTP: Advances from and Evergreen Neurotoxin. - MPTP and Motor Neurons.-MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modeling of Parkinson's Disease.- Paraquat and Parkinson's Disease.- Rotenone Preclinical Modeling of Parkinson's Disease.- N-Methyl-(R)-Salsolinol and Parkinson's Disease.- Fusion Models and "Fusioning" in Parkinsonism: 1-Benzyl-1,2,3,4-tetrahydroisoquinoline.- Amphetamines as Neurotoxins.- METH Neurotoxicity.- Neurotoxicity of MDMA.- Cocaine influence of A2/D2 receptor heteromers.- Cocaine as a Neurotoxin.- NBOMe Neurotoxicity.- Cathinone Neurotoxicity - several chapters.- Neurotoxic Vulnerability Underlying Schizophrenia Spectrum Disorders.- Molecular Mechanism and Effects of Clostridial Neurotoxins.- Botulinum Neurotoxicity.- ~3 addl subchapters on Botulinum Neurotoxicity.- Neurotoxic Effects, Mechanisms, and Outcome of 192-IgG Saporin.- TRPV1 Activators ("Vanilloids") as Neurotoxins.- Protective Agents in Parkinson's Disease:Caffeine and Adenosine A2A Receptor Antagonists.- Physical Exercise as Intervention in Parkinsonism.- Manganese Neurotoxicity and Parkinson's Disease.- Neuroinflammation and Parkinson's Disease.- Neurotoxicity in Psychostimulant and Opiate Addiction.- Homocysteine and Cerebellar Damage.- Propionic Acid, Modeling of Autism Spectrum Disorders.- 1-Me-TIQ, and endogenous Neuroprotectant.- 5-MeO-DIPT.- 3-MD-Glutaric acid.- 3-NP and Huntington's Disease.- 25C-NBOMe.- M-30.- Trace amine-associated receptor 1 and neuropsychiatric disorders.- PACAP as a Neuroprotectant.- Doxycycline as a Neuroprotectant .- PCP Modeling Amnesia.- Drug Abuse Neurotoxicity: Alcohol and Nicotine as Developmental Stressors.- Neurotrophic Factors and Ethanol Neurotoxicity.- Salsolinol and Addiction.- Snake Venom Toxins.- Salicylate Ototoxicity.- Serotoninergic Neurotoxins.- Nature of DSP-4-Induced Neurotoxicity.- 5,6- and 5,7-Dihydroxytryptamines as Serotoninergic Neurotoxins.- 2'NH(2)-MPTP: A Serotonin and Norepinephrine Neurotoxin.- Excitotoxins and Excitotoxicity.- Glutamate as a Neurotoxin.- Aspartate as a Neurotoxin.- Concept of Excitotoxicity via Glutamate Receptors .- Glutamate Neurotoxicity, Transport and Alternative Splicing of Transporters.- Excitotoxicity: A Complex Multistage Process Involving Different Mechanisms.- Glutamate Excitotoxicity Relation to Energy Failure.- Ionotropic Receptors in the Central Nervous System and Neurodegenerative Disorders.- Excitotoxicity and Axon Degeneration.- Glutamate Scavengers.- Quinolinate and Related Excitotoxins: Mechanisms of Neurotoxicity and Disease Relevanc.- Domoic Acid as a Neurotoxin.- BOAA and Neurotoxicit.- Endogenous Kynurenic Acid and Neurotoxicity.- Neuroprotection by Kynurenine Metabolites.- BMAA (beta-N-Methylamin.- Ionotropic Glutamate Receptors in Neurodegenerative and Other Disorders.- Okadaic acid modeling of Alzheimer's Disease.- Excitotoxicity in Parkinson's Disease.- Excitotoxicity and the Pathogenesis of Gliomas Excitotoxicity and Epielpsy; Epilepsy re Neurotoxicity Mechs.- Excitotoxicity in Multiple Sclerosis.- Excitotoxicity: Insights into Pathogenesis of AD.- Excitotoxicity and ALS: Insights into Pathogenesis.- Excitotoxicity and Amyotrophic Lateral Sclerosis.- Fungal Neurotoxins and ALS.- Excitotoxicity and Huntington Disease.- Excitotoxicity and Stroke.- Excitotoxicity in HIV Associated Neurocognitive Disordders.- Excitotoxicity and AIDS.- Excitotoxicity and Neuroprotection in Spinal Cord Injury.- Excitotoxicity in the Pathogenesis of Autism.- Cancer-Mediated Excitotoxicity., Excitotoxicity and Depression.- Lead and Excitotoxicity.- Glutamate and Neurodegeneration in the Retina.- Excitotoxicity and Epielpsy.- Seizures, Neurotrophin, Neuronal Death.- Neurodegenerative Aspets of Multiple System Atrophy.- Excitotoxicity in Ischemia and Reperfusion Injury.- Molecular, Cellular, and Behavioural Effects Produced by Perinatal Asphyxia: Neuroprotectants Targeting NMDA Receptor Signaling.- Neuroprotective Strategies in Amyotrophic Lateral Sclerosis Modulation ofNeurotransmitory and Neurotrophic Input to Motor Neurons.- Neuroprotection in Demyelinating Diseases: The Therapeutic Potential of the Neurotrophins.- p75NTR: A Molecule with Multiple Functions in Amyloid-beta.- Metabolism and Neurotoxicity.- Neurotrophins and ALS.- Neurotrophic Factors & NeuroAIDS.- Neuroprotection by Poly (ADP-Ribose) Polymerase 1 (PARP-1) Inhibition.- Alzheimer's Disease and Neurotoxic Aspects.- Stem Cell Therapies for Age Associated Neurodegeneration.- Pathogenesis of Alzheimer's Disease.- Experimental Approach to Alzheimer Disease.- Potential Therapeutic Effects of Statins in Alzheimer's Disease.- Excitotoxicity and Alzheimer's Disease: Treatment Challenges.- Amyloid-beta, BDNF, and Mechanism of Neurodegeneration in Alzheimer's Diseases.- Drug Treatments: hopes, challenges.- Cannabinoids and Alzheimer's.- Heavy Metal Neurotoxicity.- Trimethyltin Neurotoxicity.- Mn Neurotoxicity.- MeHG.- Cd Neurotoxicity.- Fe Neurotoxicity.- Organoselenium.- Al Neurotoxicity.- SeNeurotoxicity.- Pb Neurotoxicity.- Cuprizone modelin of Multiple sclerosis.
About the Author :
Richard M. Kostrzewa, Ph.D., Dr.h.c., obtained a Ph.D. (1971) in Pharmacology from the University of Pennsylvania, under the guidance of his Ph.D. advisor and mentor, Dr. David M. Jacobowitz, who became the inaugural Chief of Histopharmacology at the National Institutes of Mental Health. Dr. Kostrzewa, following career stints as Research Pharmacologist at the Veterans Administration Medical Center in New Orleans, Louisiana (1971–1975), adjunct Assistant Professor in the Department of Pharmacology at Tulane Medical School (1974–1976) and Department of Psychology at the University of New Orleans (1974–1977), and Associate Professor at the Louisiana State University Medical Center in New Orleans (1975–1978) joined the faculty of Pharmacology at the newly established Quillen College of Medicine at East Tennessee State University in Johnson City, Tennessee (Assoc. Prof./Professor), and has been a faculty member there for 45 years. Dr. Kostrzewa actively collaborated in research for 20 years with Prof. Ryszard Brus of the Silesian Medical University in Katowice, Poland, where he was Visiting Professor (1997–2003) and from which he received the Doctorate Honoris Causa (2005). In 2001, Dr. Kostrzewa was made an Honorary Member of the Polish Pharmacological Society. His research focus has remained on selective neurotoxins, with applications in the areas of nerve regeneration and sprouting, neurodegenerative disorders, dopamine receptor supersensitivity, and modeling of Parkinson’s disease, attention-deficit hyperactivity disorder, tardive dyskinesia, schizophrenia, and other neurologic disorders. He has authored and edited more than 10 books and more than 200 scientific papers, including the article “Pharmacological Actions of 6-Hydroxydopamine,” which in 1994 was designated in Current Contents as a “Citation Classic,” being one of the 400 most-cited papers at that time. Dr. Kostrzewa was co-founder with Prof. Dr. Juan Segura-Aguilar (University of Chile) of the Neurotoxicity Society, serving as its inaugural President, as the Society’s Treasurer for 10 years, and as its Secretary. Founder of the journal Neurotoxicity Research, he was its inaugural Editor-in-Chief, and he has served in that capacity for 24 years.
